Mark Douglas Smith Sells 1,157 Shares of Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Mark Douglas Smith sold 1,157 shares of the business’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $230.55, for a total transaction of $266,746.35. Following the completion of the sale, the director owned 9,680 shares of the company’s stock, valued at approximately $2,231,724. This represents a 10.68% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ opened at $224.66 on Friday. The company has a debt-to-equity ratio of 0.95, a quick ratio of 1.85 and a current ratio of 2.04. The company has a 50 day moving average price of $220.76 and a 200-day moving average price of $190.29. Jazz Pharmaceuticals PLC has a fifty-two week low of $105.00 and a fifty-two week high of $243.32. The stock has a market capitalization of $14.11 billion, a PE ratio of -11,227.39, a PEG ratio of 0.20 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 earnings per share (EPS) for the quarter. The company had revenue of $1.07 billion for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. Equities analysts predict that Jazz Pharmaceuticals PLC will post 22.09 earnings per share for the current fiscal year.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Jazz Pharmaceuticals announced a collaboration with AbCellera to discover and develop next-generation T-cell-engaging multispecific antibodies for GI cancers and other solid tumors, a deal that could expand JAZZ’s oncology pipeline and create future licensing or milestone revenue. Article Title
• Positive Sentiment: Multiple reports highlighted the size of the AbCellera agreement, with potential value cited in the hundreds of millions of dollars per program, reinforcing investor interest in Jazz’s ability to use external partnerships to deepen its cancer franchise. Article Title
• Neutral Sentiment: Jazz also shared late-breaking data on Xywav at SLEEP 2026, underscoring continued clinical and commercial support for its neuroscience business, though this update appears less immediate than the AbCellera news. Article Title
• Negative Sentiment: Investors may also note that Director Mark Douglas Smith sold 1,157 shares in a pre-arranged Rule 10b5-1 transaction, which can create a modest negative sentiment signal even though the sale was planned. Article Title

Analyst Ratings Changes

Several research firms have recently commented on JAZZ. Robert W. Baird set a $252.00 price target on Jazz Pharmaceuticals in a research report on Wednesday, May 6th. TD Cowen lifted their target price on Jazz Pharmaceuticals from $220.00 to $275.00 and gave the company a “buy” rating in a research note on Wednesday, May 6th. Raymond James Financial reiterated an “outperform” rating and issued a $239.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, May 6th. Barclays increased their price target on shares of Jazz Pharmaceuticals from $234.00 to $253.00 and gave the company an “overweight” rating in a research report on Wednesday, May 27th. Finally, Leerink Partners raised their price target on shares of Jazz Pharmaceuticals from $215.00 to $225.00 and gave the company an “outperform” rating in a report on Wednesday, April 22nd. Sixteen equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $246.06.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently made changes to their positions in the business. NewEdge Advisors LLC boosted its position in shares of Jazz Pharmaceuticals by 132.6% in the 1st quarter. NewEdge Advisors LLC now owns 1,975 shares of the specialty pharmaceutical company’s stock worth $373,000 after purchasing an additional 1,126 shares in the last quarter. Glenmede Trust Co. NA increased its position in Jazz Pharmaceuticals by 1.9% during the 1st quarter. Glenmede Trust Co. NA now owns 7,819 shares of the specialty pharmaceutical company’s stock valued at $1,478,000 after buying an additional 146 shares in the last quarter. Bank of America Corp DE raised its stake in Jazz Pharmaceuticals by 10.9% in the first quarter. Bank of America Corp DE now owns 1,014,800 shares of the specialty pharmaceutical company’s stock valued at $191,848,000 after buying an additional 99,656 shares during the last quarter. Tri Locum Partners LP purchased a new stake in Jazz Pharmaceuticals in the first quarter valued at about $29,995,000. Finally, Amundi boosted its holdings in Jazz Pharmaceuticals by 2,445.3% in the first quarter. Amundi now owns 55,640 shares of the specialty pharmaceutical company’s stock worth $10,519,000 after acquiring an additional 53,454 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company’s stock.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.